Organic compounds

Patent metadata

Field	Value
Publication number	US-10077267-B2
Application number	US-201515301912-A
Country	US
Kind code	B2
Filing date	Apr 3, 2015
Priority date	Apr 4, 2014
Publication date	Sep 18, 2018
Grant date	Sep 18, 2018

Abstract

The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

First claim

The invention claimed is:

1. A compound of formula I:

wherein:
R 1 is CH 3 ;
R 2 and R 3 are each independently H or D;
R 4 and R 5 are each H;
provided that R 2 , and R 3 are not both H,

and wherein D is deuterium;
in free or salt form.

2. The compound according to claim 1 , wherein R 2 and R 3 are D.

3. The compound according to claim 1 , wherein said compound is in salt form.

4. The compound according to claim 3 , wherein the salt is selected from a group consisting of toluenesulfonic, fumaric and phosphoric acid addition salt.

5. A pharmaceutical composition comprising a compound according to claim 1 , in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier.

6. A method for the treatment of a central nervous system disorder comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 5 , wherein said disorder is selected from a group consisting of anxiety, and depression.

7. The method according to claim 6 , further comprising the administration of one or more other therapeutic agents.

8. The method of claim 7 , wherein the one or more other therapeutic agents are selected from: anti-depressive agents selected from compounds that modulate GABA activity, a GABA-B agonist, a 5-HT modulator, a melatonin agonist, an ion channel modulator, a serotonin-2 antagonist/reuptake inhibitor (SARIs), an orexin receptor antagonist, an H3 agonist, a noradrenergic antagonist, a galanin agonist, a CRH antagonist, human growth hormone, a growth hormone agonist, estrogen, an estrogen agonist, a neurokinin-1 drug; and antipsychotic agents, in free or pharmaceutically acceptable salt form.

9. The method of claim 7 , wherein the one or more other therapeutic agents are antipsychotic agents selected from chlorpromazine, haloperidol, droperidol, fluphenazine, loxapine, mesoridazine molindone, perphenazine, pimozide, prochlorperazine promazine, thioridazine, thiothixene, trifluoperazine, clozapine, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone, asenapine, lurasidone, iloperidone, cariprazine, amisulpride, zotepine, sertindole, in free or pharmaceutically acceptable salt form.

10. The method of claim 7 , wherein the one or more other therapeutic agents are anti-depressive agents selected from one or more of amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, duloxetine, escitalopram, fluoxetine, fluvoxamine, imipramine, isocarboxazid, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelazine sulfate, protriptyline, sertraline, tranylcypromine, trazodone, trimipramine, and venlafaxine.

11. The method of claim 7 wherein the one or more other therapeutic agents are anti-depressive agent selected from selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants.

12. The method of claim 11 , wherein the anti-depressive agent is a SSRI.

13. The compound according to claim 4 , wherein the salt is a toluenesulfonic acid addition salt.

14. The compound according to claim 2 , wherein said compound is in salt form.

15. The compound according to claim 14 , wherein the salt is selected from a group consisting of toluenesulfonic, fumaric and phosphoric acid addition salt.

16. The compound according to claim 15 , wherein the salt is a toluenesulfonic acid addition salt.

17. A pharmaceutical composition comprising a compound according to claim 13 , in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier.

18. A pharmaceutical composition comprising a compound according to claim 16 , in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier.

Assignees

• Intra Cellular Therapies Inc

Inventors

• Mates Sharon
• Li Peng
• Wennogle Lawrence P
• Davis Robert

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P29/02

  without antiinflammatory effect · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P25/22

  Anxiolytics · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title